KX2-391 is currently also being tested for breast cancer treatment (NCT01764087) and our finding of the SL relationship between EPHB6 and SRC indicated that KX2-391 treatment may work more efficiently if applied specifically to EPHB6-deficient TNBC cells. Here, SRC is linked to breast carcinoma.